Where there's a WiL, there's a way
An International alliance dedicated to the promotion
of leadership of female lymphoma clinicians and researchers.
“WiL is committed to supporting and advocating for greater leadership of women in lymphoma globally”
We advocate for and promote equal representation at conferences, on panels, leadership committees and in research and we promote opportunities for WiL globally and celebrate the successes of our members.
We encourage networking, and engagement for WiL through dedicated meetings at major conferences and information sharing via our newsletters, webinars and website.
We facilitate education of WiL through our dedicated webinar lecture series and events run by our internationally renowned WiL members as well as promote activities run by our members.
Mentoring and role models are essential in every career path. Many of us have female trainees keen to lead research/clinical service/teaching programmes and seeing other women in these roles has inspired them to follow a similar path.
It is essential for all our junior lymphoma colleagues to see women in leadership roles within lymphoma. This not only helps the “you cannot be what you cannot see” hurdle but also leads to productive diversity on decision making boards.
A key focus of Women in Lymphoma (WiL) is to mentor other women, encouraging them to put themselves forward for career progression opportunities. By highlighting other women’s achievements through WiLing Wednesdays - a high-level education programme - it allows identification of clear role models and mentors. Through this popular educational series across lymphoma histologies, we hope to show that these leading WiL are not exceptional but should be the norm.
Nonetheless, the majority of lymphoma leaders internationally are male and mentorship is not a gender-restricted exercise. Emerging women need male mentors too, and senior women in lymphoma seek to mentor young men as well as women.
In 2021, Women in Lymphoma will be encouraging the involvement of leading men in lymphoma, as champions of change, to work with WiL on initiatives to identify and reduce barriers which may prevent women choosing or being for a leadership path in lymphoma.
Women in Lymphoma is seeking to harness the potential of all emerging lymphoma leaders, both male and female for the improvement of lymphoma research and patient care.
WiLing Wednesdays live webinar tutorial series
Series 3 – T-CELL LYMPHOMA
Wednesdays April 7, 14, 21 & 28, May 5, 2021
· Join WiL around the world as we host our third live tutorial series presenting and discussing challenging aspects of contemporary management of lymphoma.
· Series 3 will focus on T-Cell Lymphoma with sessions presented by global leading and emerging WiL.
· Sessions on Zoom are free and open to clinicians, researchers and educators in lymphoma and associated fields.
· Registration for each session via email invitation from firstname.lastname@example.org
· Session times shown in local time after registration.
UTC - Universal Time Coordinated. www.timeanddate.com
· All five sessions will be recorded and available after each session via email and at www.womeninlymphoma.org
Session 1 - Wednesday April 7, 2021
Register at this link:
· Dr Laurence De Leval – Centre Hospitalier Universitaire Vaudois, SWITZERLAND 7.30pm CEST (UTC +2)
UPDATE ON T-CELL LYMPHOMA: HEMPATH REVIEW
· Dr Kerry Savage – BC Cancer, Vancouver CANADA
10.30am PDT (UTC -7)
PRIMARY THERAPY OF COMMON PERIPHERAL T-CELL LYMPHOMA
Session 2 - Wednesday April 14, 2021
· A/Prof Siok-Bian Ng – Cancer Science Institute of SINGAPORE
8am SGT (UTC +8)
HEMPATH REVIEW OF T-CELL LYMPHOMAS COMMON IN ASIA
· Dr Yu Qin Song – Peking University Cancer Centre, Beijing CHINA
8am CST (UTC +8)
FRONTLINE & SALVAGE THERAPIES FOR T-CELL LYMPHOMAS COMMON IN ASIA
Session 3 - Wednesday April 21, 2021
Barbara Pro MD – Northwestern Medicine, Chicago USA
4pm CDT (UTC -5)
TREATMENT & OUTCOME FOR RELAPSED T-CELL LYMPHOMAS
· Neha Mehta-Shah MD – Washington University School of Medicine, St Louis USA 4pm CDT (UTC -5)
USE OF AUTOLOGOUS & ALLOGENIC TRANSPLANT FOR T-CELL LYMPHOMAS
Session 4 - Wednesday April 28, 2021
· Jasmine M. Zain MD – City of Hope CCC, Los Angeles, USA
4pm PDT (UTC -7)
NEWER THERAPIES & CLINICAL TRIALS FOR T-CELL LYMPHOMAS
· Julie Vose MD – University of Nebraska Medical Center, Omaha USA
6pm CDT (UTC -5)
Jasmine Zain MD – City of Hope CCC, Los Angeles, USA
Jia Ruan MD – Weill Cornell Medicine, New York USA 7pm EDT (UTC -4)
CASE STUDIES OF T-CELL LYMPHOMAS
Session 5 - Wednesday. May 5, 2021
CAREER DEVELOPMENT: INTERVIEWS ON PERSONAL AND CAREER CHOICES
· Sonali Smith MD – UChicago Medicine, Chicago USA 4pm CDT (UTC -5)
Interviewed by Julie Vose MD - University of Nebraska Medical Center, Omaha USA
· Prof. Judith Trotman – Concord Repatriation General Hospital, Sydney AUSTRALIA 7am AEST (UTC +10)
Interviewed by Carrie Thompson MD - Mayo Clinic, Rochester MN USA
* * * * *
CLICK HERE TO ACCESS THE RECORDINGS OF SERIES 2
ON HODGKIN LYMPHOMA (January/February 2021)
Dr Camille Golfier is an MD working in Lyon Sud Hospital, Lyon, France. She is an expert on lymphoid malignancies.
Student of well-known French haematologist, Professor Gilles Salles (MD, PhD, Lyon, France), Camille completed her medical degree at Lyon University and her physician training in Dijon and Lyon Sud Hospitals.
Aligned with comprehensive care, Camille gained a palliative care degree during her training. She also completed a Masters 2 degree in Science working on epigenetics in T-cell lymphoma with Professor Bachy (MD, PhD, Lyon, France).
Camille is currently involved in a number of clinical trials in lymphoid neoplasms as a member of the independent clinical lymphoma research network - The Lymphoma Study Association (LYSA).